Ann: PTX-100 trial advances following successful Phase 1b, page-406

First 406 Last

Share
Profile

Follow
dalts66

4,321 Posts.

2019

09/08/22

11:55

Post #: 63006595
Share

Originally posted by Shellbell: ↑

"Another round of explanations and new strategies in the clinic [from Amgen] isn’t likely going to be well received by anyone. But don’t expect anyone to lose interest now. Mastering KRAS has game-changing potential in oncology — for whoever comes out on top."

Thanks for keeping us uptodate with what's with KRAS trials, Dalts. Interesting that Lumakras achieves positive outcomes as a monotherapy but disappointed in combo with the PD1 checkpoint inhibitor. The concern is that perhaps KRAS targeted therapies may not be as successful as had hoped in combo with immunotherapy drugs. Attention will now turn to Mirati with their more promising combo results to date - in the hope that Amgen's results aren't indicative of a class response.

Certainly an interesting space. It was brought up in the recent panel discussion with Dan Shelly who presented for PTX, that the FDA is focusing in on targeted therapies. The outcomes to our PTX100 expansion trial is going to have much attention on it. Its safety as a monotherapy has already been established to a large degree... so, now its all about the efficacy data (and, to a lesser degree, any other interesting indications it may throw up as a target against KRAS).a

Can't not sign off without mentioning the sad loss of Olivia Newton-John. Such a wonderful lady who battled cancer for decades, did so much to help others and touched people across the world with her generosity, determination and down-to-earth nature. Her legacy will live on with the Olivia Newton-John Cancer Research and Wellness Institute in Melbourne. Sad day.

Expand

KRAS has lots of potential. Only early days but showing so much promise.
The PTX much broader spectrum makes PTX100 look exciting. The expansion trial will be important.

PTX Price at posting: 17.0¢ Sentiment: Buy Disclosure: Held
16 Upvote

0 Great analysis

Reply

Top Stories

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

PL3

Patagonia looks to raise $2.15M for South American exploration and development

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

There are more pages in this discussion • 1 more message in this thread...

First 406 Last

Add PTX (ASX) to my watchlist

(20min delay)
Last 4.4¢		Change 0.003(7.32%)		Mkt cap ! $35.43M

Open	High	Low	Value	Volume
4.1¢	4.4¢	4.0¢	$20.95K	507.0K

Buyers (Bids)

No.	Vol.	Price($)
8	216927	4.0¢

Sellers (Offers)

Price($)	Vol.	No.
4.4¢	238807	2

View Market Depth

No.	Vol.	Price($)
8	216927	0.040
4	374358	0.039
3	750222	0.038
9	742682	0.037
7	598944	0.036

Price($)	Vol.	No.
0.044	238807	2
0.045	423919	4
0.046	298002	2
0.047	488389	2
0.048	200000	1

Last trade - 16.10pm 09/07/2024 (20 minute delay)

PTX (ASX) Chart

Ann: PTX-100 trial advances following successful Phase 1b, page-406

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Patagonia looks to raise $2.15M for South American exploration and development

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: PTX-100 trial advances following successful Phase 1b, page-406

Top Stories

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Patagonia looks to raise $2.15M for South American exploration and development

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News